[8-K] Nuburu, Inc. Reports Material Event

Rhea-AI Filing Summary

Bluejay Diagnostics (BJDX) filed an 8-K announcing an amendment, dated 23-Jul-2025, to its amended & restated License and Master Supply Agreements with Toray Industries.

• Manufacturing deadline extended: the company now has until 23-Oct-2026 (previously 23-Oct-2025) to qualify an alternative site to produce Symphony cartridges.
• Know-how fully transferred: Toray confirms it has delivered all technical know-how required under the License Agreement and has no further obligation to provide assistance.
• Final component purchase: Bluejay will pay Toray USD 71,212 for a last shipment of chip components ahead of the Supply Agreement’s scheduled expiry on 23-Oct-2025.

No additional financial statements were included. The amendment secures component supply and provides an extra year to localize manufacturing, but removes Toray’s future technical support, placing execution risk squarely on Bluejay.

Positive

• 12-month deadline extension reduces immediate production pressure and potential contract default risk.
• Final component order secured ensures uninterrupted Symphony cartridge supply through Supply Agreement expiry.

Negative

• No further technical assistance from Toray heightens execution risk for BJDX’s new manufacturing site.
• Supply Agreement still ends 23-Oct-2025, creating a reliance on successful in-house production thereafter.

Insights

Medical Diagnostics Industry Specialist

TL;DR – Extension eases near-term supply risk but shifts technical burden to BJDX; neutral overall.

Granting an extra year to stand up an alternative cartridge plant reduces immediate production risk and aligns with the Symphony platform’s commercialization timeline. The one-time USD 71k purchase is immaterial (<1% cash). However, Toray’s completed know-how transfer means Bluejay loses access to ongoing engineering assistance, elevating execution and validation risk for the new facility. Investors should monitor capital needs and FDA regulatory timelines tied to Symphony launch.

Risk Analyst

TL;DR – Deadline deferral buys time; loss of Toray support could be a future bottleneck.

The filing is not materially impactful to near-term financials but influences operational risk profile. Extension avoids potential breach of contract in 2025 and secures essential chips before supply agreement lapses. Nevertheless, Bluejay must now independently establish GMP-compliant manufacturing within 15 months of supply cessation—a tight window. Any delay could hinder product roll-out and revenue conversion. Impact rating: neutral.

false000181421500018142152025-07-222025-07-22

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): July 22, 2025

Nuburu, Inc.

(Exact name of Registrant as Specified in Its Charter)

Delaware			001-39489	85-1288435
(State or Other Jurisdiction of Incorporation)			(Commission File Number)	(IRS Employer Identification No.)
7442 S Tucson Way Suite 130
Centennial, Colorado				80112
(Address of Principal Executive Offices)				(Zip Code)

Registrant’s Telephone Number, Including Area Code: (720) 767-1400

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.0001 per share		BURU		NYSE American LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

On July 22, 2025, the NYSE notified Nuburu, Inc. (the “Company”) that it had accepted the Company’s plan outlining definitive actions that the Company has taken or will take to regain compliance with NYSE’s continued listing standards (the “Compliance Plan”) and granted a plan period through October 29, 2026 (the “Plan Period”).

As previously reported, on April 29, 2025, received a Notice of Noncompliance (the “Notice”) from NYSE Regulation indicating that the Company was not in compliance with Section 1003(a)(i) of the NYSE American Company Guide (the “Company Guide”) since it reported stockholders’ deficit of $(37.8) million at December 31, 2024 and has had losses in the two most recent fiscal years.

The NYSE will review the Company periodically for compliance with the Compliance Plan. If the Company is not in compliance with the continued listing standards by October 29, 2026, or if the Company does not make progress consistent with the Compliance Plan during the Plan Period, NYSE may initiate delisting proceedings as appropriate. However, the Company may appeal a staff delisting determination in accordance with the Company Guide.

NYSE’s acceptance of the Compliance Plan has no immediate effect on the listing or trading of the Company’s securities and the Company’s common stock will continue to trade on the NYSE American under the symbol “BURU” during the Plan Period with the designation of “.BC” to indicate that the Company is not in compliance with the NYSE American’s continued listing standards.

The Company continues to work diligently to regain compliance.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.		Description
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

Forward-Looking Statements

This report contains certain "forward-looking statements" within the meaning of the United States Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical fact contained in this report may be forward-looking statements. Some of these forward-looking statements can be identified by the use of forward-looking words, including "may," "should," "expect," "intend," "will," "estimate," "anticipate," "believe," "predict," "plan," "seek," "targets," "projects," "could," "would," "continue," "forecast" or the negatives of these terms or variations of them or similar expressions. All forward-looking statements are subject to risks, uncertainties, and other factors which could cause actual results to differ materially from those expressed or implied by such forward-looking statements. All forward-looking statements are based upon estimates, forecasts, and assumptions that, while considered reasonable by the Company and its management, are inherently uncertain. Many factors may cause the Company's actual results to differ materially from current expectations, including but are not limited to: (1) the ability to meet security exchange listing standards; (2) the impact of the previously announced foreclosure, which resulted in the loss of the Company’s patent portfolio; (3) failure to achieve expectations regarding business development and the Company’s announced acquisition strategy; (4) the inability to access sufficient capital to operate or pursue the Company’s strategy; (5) the inability of the Company to grow and manage growth profitably, maintain relationships with customers and suppliers, and retain its management and key employees; (6) changes in applicable laws or regulations; (7) adverse impacts of general economic, business, and competitive factors; (8) volatility in the financial system and markets; (9) the inability to consummate recently announced transactions or realize the anticipated benefits from such transactions; and (10) other risks and uncertainties set forth in the sections entitled "Risk Factors" and "Cautionary Note Regarding Forward-Looking Statements" in the Company’s most recent periodic report on Form 10-K or Form 10-Q and other documents filed with the SEC from time to time. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Nothing in this report should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved. You should not place undue reliance on forward-looking statements, which speak only as of the date they are made. The Company does not give any assurance that it will achieve its expected results. The Company assumes no obligation to update or revise these forward-looking statements, whether as a result of new information, future events or otherwise, except as otherwise required by applicable law.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

			NUBURU, INC.
Date:	July 28, 2025	By:	/s/ Alessandro Zamboni
			Name: Alessandro Zamboni Title: Executive Chairman

FAQ

What agreement did BJDX amend with Toray?

Bluejay amended its License Agreement and Master Supply Agreement dated 23-Jul-2025.

How long is the new manufacturing deadline for Bluejay Diagnostics?

The company now has until 23-Oct-2026 to establish an alternative Symphony cartridge production site.

Will Toray provide further technical support after this amendment?

No. Toray confirmed it has delivered all required know-how and owes no additional assistance.

What is the cost of the final chip component supply BJDX will purchase?

Bluejay will pay USD 71,212 for the last shipment of chip components.

When does the Master Supply Agreement between BJDX and Toray expire?

The Supply Agreement remains set to expire on 23-Oct-2025.